[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tourette-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tourette-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,39,65,94,119,143,181,206,230,259,279,310,347,366,390,427,445,474,501,525,547,575,600],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100053704","phase-1-transcranial-ultrasound-stimulation-for-tourette-syndrome-100053704",false,"NCT07699783","Transcranial Ultrasound Stimulation for Tourette Syndrome","TUS-TS","Inclusion Criteria:\n\n* Diagnosis of Tourette Syndrome according to DSM-5 criteria\n* a total motor or vocal tic severity sub-score of at least 15, or a total tic severity score greater than 22 on the Yale Global Tic Severity Rating Scale (YGTSS)\n* a stable medication regimen during the 3 months prior, clinically stable in any psychiatric comorbidities\n\nExclusion Criteria:\n\n* Contraindications for MRI","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a phase 1 clinical trial investigating the use of low-energy Transcranial Ultrasound Stimulation (TUS) to treat Tourette Syndrome (TS).\n\nObjectives and Background. TS is a neurodevelopmental condition marked by motor and vocal tics that often resist standard pharmacological or behavioral treatments. Current neuromodulation options like Deep Brain Stimulation (DBS) are invasive, while non-invasive methods like TMS lack the precision to reach deep brain structures.\n\nThe study aims to:\n\n1. Evaluate tolerability: Assess TUS safety in older adolescents and adults with TS.\n2. Test efficacy: Compare TUS at the intralaminar thalamic nuclei (CM\u002FPf\u002FVoi) and the supplementary motor area (SMA) against a sham treatment to see if it reduces tic frequency and severity.\n3. Optimize protocols: Determine if dual-target or multiple-session stimulation is more effective than single-target or single-session protocols.\n\nTUS uses low energy, pulsed, focused ultrasound to induce transient neuromodulatory responses lasting up to 60 minutes. TUS can precisely target deep structures like the thalamus.\n\nStudy Methods\n\n* Design: A phase 1, double-blind, crossover trial.\n* Participants: 20 individuals (ages 16+) with a diagnosis of TS and significant tic severity (YGTSS score \\> 22 or sub-score \\> 15).\n* Procedure: Participants receive four different modalities over four separate weeks, with 7-day washouts:\n\n  * TUS of the CM\u002FPf\u002FVoi only.\n  * TUS of the SMA only.\n  * Combined TUS of both targets.\n  * Sham TUS.\n* Evaluation: The primary endpoint is the percent change on the Rush Video-Based Tic Rating Scale (RVBTRS). Secondary measures include the Yale Global Tic Severity Scale (YGTSS) and the Premonitory Urges for Tics Scale (PUTS).\n\nBecause TUS requires extreme precision to hit deep brain targets, every participant undergoes a comprehensive imaging protocol using a 3T GE UHP scanner.\n\n* Mapping the Targets: We use Diffusion Tensor Imaging (DTI) and Tractography to locate the specific \"wiring\" of the individual's brain. This allows to find:\n\n  * The CM\u002FPf\u002FVoi (Centromedian-parafascicular complex) in the thalamus.\n  * The SMA (Supplementary Motor Area) in the cortex.\n* Precision Imaging: High-resolution 1 mm-isotropic T1-weighted, T2-weighted, and Zero Echo Time (ZTE) images are used. ZTE is particularly important as it helps the BabelBrain software account for the thickness and density of the skull, which can deflect ultrasound waves.\n* Real-Time Tracking: During the actual stimulation, the team uses a Brainsight neuro-navigation system. This acts like a GPS, using the patient's MRI \"map\" to ensure the ultrasound transducer is perfectly aligned with the target.\n\nInnovation This is the first human study to apply TUS to TS patients. By targeting both deep and cortical regions independently or simultaneously, the researchers aim to modulate the \"network-level\" connectivity implicated in tic generation.\n\nTechnical Ultrasound Parameters The study uses a custom 128-element phased-array transducer (Sonic Concepts H317) to deliver TUS.\n\n* Core Settings:\n\n  * Frequency: 250 kHz.\n  * Intensity: spatial-peak pulse-average intensity (ISPPA) of 10 W\u002Fcm2\n* Targeting \\& Safety:\n\n  * BabelBrain Software: Calculates real-time acoustic simulations to correct for bone aberrations and ensure the Mechanical Index (MI) stays below 1.9 and thermal rise remains under 2°C.\n  * Electronic Steering: Allows the focal spot to be moved without physically repositioning the device, enabling coverage of large areas like the SMA or deep structures like the CM\u002FPf\u002FVoi complex.\n* Biological Protocols:\n\n  * Inhibitory: pulse repetition frequency (PRF), 10% duty cycle, lasting 120 seconds.\n  * Excitatory: \"theta burst\" PRF, 10% duty cycle, lasting 80 seconds. Clinical Assessment Criteria\n\nThe trial employs three main scales to capture both objective tic data and subjective patient experiences:\n\n1. Rush Video-Based Tic Rating Scale (RVBTRS):\n\n   * The Primary Measure: This is the only validated tool that provides an objective assessment by analyzing 10-minute video recordings.\n   * Method: Two blinded evaluators count tics and rate their severity across two views: a close-up (head\u002Fshoulders) and a full-body frontal view.\n   * Focus: It specifically measures the patient's ability to actively inhibit tics during the recording.\n2. Yale Global Tic Severity Scale (YGTSS):\n\n   * The Gold Standard: A clinician-rated interview that assesses symptoms over the prior 7-10 days.\n   * Scoring: It rates motor and phonic tics separately on five dimensions: number, frequency, intensity, complexity, and interference.\n   * Baseline Requirement: To participate in the trial, patients must have a total tic severity score of at least 22 (or a sub-score of 15).\n3. Premonitory Urges for Tics Scale (PUTS):\n\n   * Self-Report: A 9-item questionnaire where patients rate the intensity of pre-tic sensations (like pressure, itchiness, or tension) on a scale of 1 to 4.\n   * Interpretation: Scores range from 9 to 36; higher scores reflect more distressing urges.",[26],"Tourette Syndrome","NOT_YET_RECRUITING","2026-07-09",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-08-01",{"date":35,"type":20},"2028-06-01",{"name":37,"class":38},"University of Calgary","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100568247","phase-2-cbittms-r33-phase-100568247","NCT06678737","CBIT+TMS R33 Phase","Inclusion Criteria:\n\n* Age 12-21 years at time of enrollment.\n* Current chronic motor and\u002For vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months. Tics must not be due to a medical condition or the direct physiological effects of a substance.\n* At least moderate tic severity, defined as a Yale Global Tic Severity Scale total score ≥14 (≥9 for those with motor or vocal tics only).\n* Full scale IQ greater than 70.\n* Child, consenting parent, and adult participant required to have English fluency and literacy to ensure comprehension of study measures and instructions.\n* To increase external validity of findings, we will include participants taking psychotropic medications that have been stable for 6 weeks and expect to remain stable for the approximately 3-week intervention protocol (with the exception of those taking neuroleptic\u002Fantipsychotic medications). Those who previously received tic-specific therapy will be included if they meet the tic severity criterion.\n\nYouth receiving other forms of psychotherapy will be included provided these treatments are not focused on tics. All concurrent treatments will be monitored during the study period.\n\nExclusion Criteria:\n\n* Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, epilepsy or seizure disorders, traumatic brain injury, brain tumor, stroke, implanted medical devices or metallic objects in the head, current pregnancy or girls of childbearing age not using effective contraception, or any other medical condition deemed serious or contraindicated by a study physician.\n* Inability to undergo MRI (e.g., metal in body, claustrophobia, orthodontia)\n* Active suicidality.\n* Previous diagnosis of psychosis or cognitive disability.\n* Substance abuse or dependence within the past year.\n* Concurrent psychotherapy focused on tics.\n* Neuroleptic\u002Fantipsychotic medications.\n* Pregnant according to the medical history or a urine pregnancy test; and menstruating individuals capable of becoming pregnant and not using a highly effective form of contraception (FDA-approved hormonal contraceptive, IUD, tubal ligation)\n* Taking a medication that has not reached stability criterion (same medication and dose for 6 weeks with no planned changes over the intervention period)","12 Years","21 Years",{"count":48,"type":20},60,[50],"PHASE2","Chronic tics are a disabling neuropsychiatric symptom associated with multiple child-onset mental disorders. Chronic tics affect 1-3% of youth 1 and are associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, peer victimization, and a fourfold increased risk of suicide compared to the general population. Large randomized trials have demonstrated the superiority of CBIT over supportive therapy in child and adult patients. However, in these trials, only 52% of children and 38% of adults showed clinically meaningful tic improvement, meaning that 50-60% of patients do not benefit from CBIT. CBIT success relies on an ability to suppress tics that many youth lack. The central aim of CBIT is to enhance voluntary tic suppression. Better tic suppression ability drives CBIT improvement 10 and predicts lower tic burden over the course of illness. During the core CBIT procedure, competing response training, patients learn to inhibit tics by engaging in a competing motor action. However, research shows that many youth lack this fundamental tic suppression ability that CBIT aspires to enhance.\n\nThis study will examine the clinical and neural effects of a treatment combining Comprehensive Behavioral Intervention for Tics (CBIT) and transcranial magnetic stimulation (TMS) to the supplementary motor area (SMA) in young people with tic disorder.",[53,26],"Tics","RECRUITING","2026-05-18",{"date":57,"type":31},"2026-05-20",{"date":59,"type":31},"2025-02-27",{"date":61,"type":20},"2030-07-15",{"name":63,"class":38},"University of Minnesota",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":64},"100547491","remote-delivery-of-a-mindfulness-based-intervention-for-tics-100547491","NCT06408662","Remote Delivery of a Mindfulness-based Intervention for Tics","MBIT","Inclusion Criteria:\n\n1. be ≥18 years of age;\n2. meet diagnostic criteria for a primary or co-primary diagnosis of Tourette Syndrome or a Persistent Motor or Vocal Tic Disorder on a structured clinical interview;\n3. have moderate or greater tic severity as evidenced by a YGTSS Total Tic Score of \\>14 (when motor and vocal tics are present) or \\>10 (when only motor or vocal tics are present);\n4. be medication free and\u002For on a stable dose of psychiatric medication 8 weeks prior to study participation;\n5. be not engaged in psychotherapy for non-TS conditions and\u002For be on a stable course of therapy for 6 months prior to study participation\n6. be fluent in English;\n7. have access to a smart phone and\u002For tablet.\n\nExclusion Criteria:\n\n1. a current diagnosis of substance use disorder, psychosis, mania or another condition that requires another form of care;\n2. severe current suicidal\u002Fhomicidal ideation and\u002For self-injury requiring medical intervention;\n3. concurrent psychotherapy for TS;\n4. prior extensive experience with mindfulness and\u002For meditation.",{"count":73,"type":20},150,[75],"NA","This research study is being done to compare a mindfulness-based intervention for tics (MBIT) to psychoeducation with relaxation and supportive therapy (PRST) for individuals with Tourette's syndrome or Persistent Tic Disorders (collectively TS). It is the investigator's hope that this information cam be used to improve current treatments for individuals with TS.",[26,78,79,80,81,82,83,84],"Tourette's Disorder","Chronic Motor Tic Disorder","Chronic Vocal Tic Disorder","Persistent Motor Tic Disorder","Persistent Vocal Tic Disorder","Persistent Tic Disorder","Tic Disorders","2026-05-07",{"date":87,"type":31},"2026-05-11",{"date":89,"type":31},"2024-05-23",{"date":91,"type":20},"2028-12",{"name":93,"class":38},"Johns Hopkins University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":64},"100427873","longitudinal-impact-of-stressors-in-adults-with-tourette-syndrome-100427873","NCT04851678","Longitudinal Impact of Stressors in Adults With Tourette Syndrome","LISA-TS","Inclusion Criteria:\n\n* adults (\\>18) meeting Diagnostic and Statistics Manual, 5th edition (DSM-V) criteria for Tourette syndrome, chronic motor tic disorder, or chronic vocal tic disorder\n* ability to provide informed consent\n* English proficiency\n\nExclusion Criteria:\n\n\\- significant medical, neurologic, or psychiatric diagnoses (e.g. uncontrolled epilepsy, chronic heart failure, schizophrenia) besides TS and its commonly co-occurring psychiatric diagnoses",{"count":102,"type":20},140,"OBSERVATIONAL","The Investigators propose a two-year, longitudinal pilot study of TS adults (\\>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).",[26],[107,108,109],"Stress","Environmental stress","Psychosocial stress","2026-04-28",{"date":112,"type":31},"2026-05-05",{"date":114,"type":31},"2021-09-30",{"date":116,"type":20},"2027-06-30",{"name":118,"class":38},"Vanderbilt University Medical Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":142},"100449008","phase-2-sci-110-in-the-treatment-of-tourette-syndrome-100449008","NCT05126888","SCI-110 in the Treatment of Tourette Syndrome","A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.","Inclusion Criteria:\n\n1. Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)\n2. Male and female subjects with an age between ≥18 and ≤65 years\n3. Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) \\>14\n4. Clinical Global Impression-Severity Score (CGI-S) ≥4\n5. Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study\n6. Signed written informed consent and willingness to comply with treatment and follow-up procedures\n7. Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study\n8. Women of child-bearing potential must have a negative pregnancy test (e.g., urine human chorionic gonadotropin \\[hCG\\]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year as when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Women without childbearing potential may enter this study. Women without childbearing potential defined as follows:\n\n   * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or\n   * hysterectomy or uterine agenesis or\n   * ≥ 50 years and in postmenopausal state ≥ 1 year or\n   * \\< 50 years and in postmenopausal state ≥ 1 year with urine FSH \\> 40 IU\u002Fl and urine oestrogen \\< 30 ng\u002Fl, or serum follicle stimulating hormone (FSH) in the post-menopausal range or a negative oestrogen test.\n9. Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study\n\nExclusion Criteria:\n\n1. Comorbid obsessive-compulsive disorder (OCD), attention deficit\u002Fhyperactivity disorder (ADHD), depression, and anxiety disorder when unstable or in need of an initial adjustment for a therapy-according to the investigator's judgment\n2. Presence of severe psychiatric conditions such as developmental disability, psychotic illness and bipolar disorder- according to the investigator's judgment\n3. Ongoing behavioural treatment for tics\n4. History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder\n5. Current clinical diagnosis of substance abuse or dependence\n6. History of cannabis dependence\n7. Secondary and other chronic tic disorders or other significant neurological disorders\n8. Known severe cardiac diseases, known severe cardiovascular diseases, known positivity for human immunodeficiency virus (HIV), hepatitis C, hepatitis B, or other severe hepatic and renal disorders by history\n9. Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence)\n10. Use of cannabis or cannabinoid-based medicine (CBM) in the 30-day period prior to study entry and\u002For positive delta-9-tetrahydrocannabinol (THC) urine test at baseline\n11. Positive urine ß-HCG pregnancy test\n12. Pregnant or breast-feeding women\n13. Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study\n14. Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and ingredients of study medication (e.g., cannabis, cannabinoids, or sesame oil)\n15. Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject\n16. Subjects who are employees of the sponsor or employees or close relatives of the investigator\n17. Subjects with active suicidal ideation and behaviour (SI\u002FB) according to the Columbia-Suicide Severity Rating Scale (C-SSRS) and\u002For subjects that have attempted suicide in the past.","65 Years",{"count":128,"type":20},164,[50],"To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.",[26],"2026-04-16",{"date":134,"type":31},"2026-04-21",{"date":136,"type":20},"2026-06",{"date":138,"type":20},"2028-02",{"name":140,"class":141},"Neurothera Labs Inc.","INDUSTRY",3,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":17,"enrollmentInfo":152,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":154,"conditions":155,"keywords":164,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":64},"100561089","a-multicenter-pediatric-deep-brain-stimulation-registry-100561089","NCT06585618","A Multicenter Pediatric Deep Brain Stimulation Registry","Multicenter Pediatric Deep Brain Stimulation Registry","DBS-R","Inclusion Criteria:\n\n* Female or male patients between ages of 0-18 years.\n* Having received or scheduled to receive DBS for any neurological movement disorder.\n* Parents or legal guardians are able to provide written consent for prospective enrollment.","0 Years",{"count":153,"type":20},100,"There is limited data on outcomes for children who have undergone deep brain stimulation (DBS) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. This study aims to develop a multicenter pediatric DBS registry that allows multiple sites to share clinical pediatric DBS data. The primary goals are to enable large-scale, well-powered analyses of the safety and efficacy of DBS in the pediatric population and to further explore and refine DBS as a therapeutic option for children with dystonia and other hyperkinetic movement disorders. Given the current scarcity of evidence available to clinicians, this centralized multicenter repository of clinical data is critical for addressing key research questions and improving clinical practice for pediatric DBS.",[156,157,158,26,159,160,161,162,163],"Dystonia","Epilepsy in Children","Cerebral Palsy","Obsessive-Compulsive Disorder","Neurologic Disorder","Movement Disorders in Children","Movement Disorders","Deep Brain Stimulation",[163,165,166,167,168,169,170,171],"DBS","movement disorder","movement disorders in children","dystonia","chorea","dyskinesia","epilepsy","2026-03-16",{"date":174,"type":31},"2026-03-18",{"date":176,"type":31},"2024-07-30",{"date":178,"type":20},"2029-07-30",{"name":180,"class":38},"Boston Children's Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100351105","sensory-symptoms-in-tourette-syndrome-100351105","NCT03851484","Sensory Symptoms in Tourette Syndrome","SenST","Inclusion criteria:\n\n* 18 years of age or older\n* Ability to provide informed consent and answer self-report questionnaires independently in English\n* Diagnosis of Tourette syndrome (TS), chronic motor tic disorder, or chronic vocal tic disorder\n\nExclusion criteria:\n\n* History of psychotic disorder\n* History of significant neurologic disorder (e.g., stroke) other than TS or another chronic tic disorder",{"count":189,"type":20},214,"Patients with tics will be asked to complete a series of validated questionnaires (in electronic and\u002For paper format) regarding symptoms and conditions often associated with Tourette syndrome, including premonitory urges, sensory experiences, inattention, obsessive-compulsive tendencies, anxiety, and depression. Participants will also be asked to complete a quality of life assessment. This series of questionnaires will be administered annually.",[26],[193,194,195,196],"Tourette syndrome","premonitory urge","sensory dysregulation","hypersensitivity","2026-03-10",{"date":199,"type":31},"2026-03-13",{"date":201,"type":31},"2019-04-17",{"date":203,"type":20},"2028-12-31",{"name":118,"class":38},2,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":64},"100396973","observational-database-on-deep-brain-stimulation-in-tourette-syndrome-100396973","NCT04449068","Observational Database on Deep Brain Stimulation in Tourette Syndrome","Pre et Post-operative Evaluation of Patients With Tourette Syndrome Treated With High Frequency Bilateral Stimulation of the Anterior Part of the Internal Pallid Globus","POSTSTIC","Inclusion Criteria:\n\n* Tourette syndrome severe and drug-resistant eligible for bilateral deep brain stimulation\n* Person who voluntarily and knowledgeably agreed to participate in the study\n\nExclusion Criteria:\n\n* Non affiliation to a French social security system (recipient or assign) excluding AME","15 Years",{"count":19,"type":20},"Within an ongoing deep brain stimulation (DBS) program for Tourette syndrome (TS) at the Department of Neurology, Pitié-Salpêtrière Hospital, Paris\u002FFrance, the investigator team plans to evaluate patients pre-operatively and then at one year intervals post-operatively until the 5-year mark has been achieved. The investigator team will investigate tic severity, psychiatric co-morbidities, quality of life, and neuropsychological measures.",[26],[219,220],"bilateral deep brain stimulation","Tourette syndrome,","2026-03-04",{"date":223,"type":31},"2026-03-06",{"date":225,"type":31},"2021-01-12",{"date":227,"type":20},"2036-06-12",{"name":229,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100627549","characterising-sleep-disorders-in-children-with-tourette-syndrome-100627549","NCT07450079","Characterising Sleep Disorders in Children With Tourette Syndrome","A Retrospective Multimodal Analysis of Sleep in Children With Tourette Syndrome: Integrating Clinical History, Blood Biomarkers (Vitamin D and Ferritin Levels), Actigraphy, Video Polysomnography, and Subjective Tic Assessments","Inclusion Criteria:\n\n* Patients already under investigation by Evelina London Children's Hospital for sleep disturbances\n* Diagnosis of Tourette Syndrome in accordance with the International Classification of Diseases (ICD-10;F95.2)\n* Ages 6-17 at time of recruitment, and not between transition or due to transition to adult services\n* Have had a successful and compliant PSG, ideally within 6 months of recruitment\n* Participants able to understand patient information and can provide informed assent\n* Participants have parent and\u002For guardian willing to provide informed consent on behalf of the child\n\nExclusion Criteria:\n\n* Any physician diagnosed chronic medical condition that could impact their study participation\n* Non-verbal participants without access to appropriate communication support\n* Non-English-speaking participants without access to appropriate translator","6 Years","17 Years",{"count":240,"type":20},34,"Healthy sleep is essential for a young person's growth, development, and wellbeing. It is estimated that up to 80% of young people with Tourette Syndrome experience sleep difficulties. Tourette Syndrome is a neurological condition that causes sudden, unwanted, and repeated motor movements and vocal sounds, known as tics. Previous studies have shown that children with this condition have poorer sleep quality, specifically increased awakenings and difficulties falling or staying asleep. These challenges highlight the need to better understand sleep problems in young people with Tourette Syndrome.\n\nThis study will assess whether children's tics affect their sleep quality by measuring how often tics occur during sleep and how severe they are. To do this, the investigators will use a new Tic index to measure the impact of tics during an overnight sleep study. A watch like device that tracks movement and light levels will also be employed to help estimate when someone is asleep or awake. Together, these measures enable a clear comparison between the sleep of children with Tourette Syndrome and those without. Children will also complete a questionnaire to gain insights into their personal experiences and how they perceive tics to influence their sleep.\n\nThe specific objectives include:\n\n1. Compare the sleep patterns of children with Tourette syndrome (TS) to those of children without TS, to see whether tics are linked to any differences in sleep.\n2. Assess how accurately the tic measurements identify tics during sleep, to see whether they could be useful in future research.\n3. Explore whether tic activity changes during different stages of sleep in children with TS.\n4. Look at how the results from sleep recordings (such as movement monitors and tic measurements) relate to questionnaire responses about sleep and tics.\n\nResults from this study can be used to support future research that continues to improve the management and treatment of sleep problems in Tourette Syndrome children.",[26],[26,244,245,246,247,248,249,250],"sleep disturbances","tic index","arousals","polysomnography","actigraphy","questionnaire","tics in sleep","2026-02-27",{"date":221,"type":31},{"date":254,"type":20},"2026-03-01",{"date":256,"type":20},"2027-09-30",{"name":258,"class":38},"Steffi Baker",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":21,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":64},"100526579","epidemiology-of-assertiveness-and-emotion-management-disorders-in-people-with-tourettes-syndrome-100526579","NCT06136572","Epidemiology of Assertiveness and Emotion Management Disorders in People With Tourette's Syndrome","AFFIRMATICS","Inclusion Criteria:\n\n* Tourette syndrome\n* Participants aged 18 years or over\n\nExclusion Criteria:\n\n* Participants under legal protection\n* Inability to complete questionnaires alone",{"count":267,"type":20},350,[75],"The goal of this study is to evaluate the proportion of assertiveness difficulties in Tourette syndrome. Participants will complete several e-questionnaires (on assertiveness, Tourette severity, quality of life, self-esteem and comorbidities like depression, anxiety...).",[26],"2026-02-25",{"date":251,"type":31},{"date":274,"type":31},"2024-05-06",{"date":276,"type":20},"2026-11-05",{"name":278,"class":38},"University Hospital, Clermont-Ferrand",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":285,"sex":16,"minAge":286,"maxAge":238,"enrollmentInfo":287,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":64},"100560406","sensorimotor-and-psychosocial-trajectories-in-adolescents-with-tic-disorder-100560406","NCT06576726","Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder","* Inclusion criteria for adolescents with tic disorder:\n\n  * adolescent age 11-17 years of age\n  * adolescent diagnosis of chronic tic disorder (Tourette syndrome, chronic motor tic disorder, chronic vocal tic disorder)\n  * English-speaking adolescent and caregiver\u002Fadult proxy (as validated questionnaires are in English)\n  * adolescent and caregiver\u002Fadult proxy willingness and ability to complete relevant questionnaires\n* Exclusion criteria for for adolescents with tic disorder:\n\n  * cognitive or attentional impairment precluding ability of adolescent or caregiver\u002Fadult proxy to complete questionnaires and other study measures\n  * adolescent diagnosis of autism spectrum disorder (ASD) or psychotic disorder\n  * adolescent diagnosis of pervasive genetic disorder besides chronic tic disorders and their known comorbidities\n  * adolescent with severe medical conditions unrelated to chronic tic disorders (e.g. uncontrolled seizures, prominent heart conditions)\n  * other variables that might influence ratings outside of the typical presentation of chronic tic disorders\n* Additional exclusion criteria for EEG tasks for chronic tic disorder sample\\*\\*\n\n  * adolescent treatment with stimulant medications or anti-seizure medications within the past 30 days\n  * use of marijuana or recreational substances within the past 30 days\n  * history of seizure\n  * history of hearing loss or abnormalities\n  * history of neuropathy or overt sensory deficit\n  * history of brain surgery or skull-penetrating\u002Fdeforming trauma\n  * history of stroke, brain cancer, or other significant neurologic illness\u002Fdisorder \\*\\* Individuals excluded based on these criteria are ineligible for the EEG portion of the study but can complete the remainder of the study measures.\n* Inclusion criteria for control (neurotypical adolescent) participants\n\n  * adolescent age 11-17 years of age\n  * English-speaking adolescent and caregiver\u002Fadult proxy (as validated questionnaires are in English)\n  * adolescent and caregiver\u002Fadult proxy willingness and ability to complete relevant questionnaires\n* Exclusion criteria for control sample\n\n  * history of tics, ADHD, OCD, or other significant neurodevelopmental or neuropsychiatric disorder.\n\n    \\*\\* Note: adolescents with history of mood or anxiety disorder are eligible.\n  * cognitive or attentional impairment precluding ability of adolescent or caregiver\u002Fadult proxy to complete questionnaires and other study measures\n  * adolescent diagnosis of autism spectrum disorder (ASD) or psychotic disorder\n  * adolescent diagnosis of pervasive genetic disorder\n  * adolescent with severe medical conditions (e.g. uncontrolled seizures, prominent heart conditions)\n  * other variables that might influence ratings\n* Additional exclusion criteria for EEG tasks for control sample\\*\n\n  * adolescent treatment with stimulant medications or anti-seizure medications within the past 30 days\n  * use of marijuana or recreational substances within the past 30 days\n  * history of seizure\n  * history of hearing loss or abnormalities\n  * history of neuropathy or overt sensory deficit\n  * history of brain surgery or skull-penetrating\u002Fdeforming trauma\n  * history of stroke, brain cancer, or other significant neurologic illness\u002Fdisorder",true,"11 Years",{"count":288,"type":20},351,"Individuals with tic disorders have lower quality of life, sensory and movement difficulties, and poorer mental, social, and physical health compared to the general population. Current clinical care for individuals with tic disorders is limited: no interventions are proven to prevent or stop the disorder exist, and most treatments focus solely on tics, though other symptoms often affect quality of life more than tics. To develop new treatments and improve care for people with tics, researchers need to better understand the different symptoms people experience and how the brain causes these symptoms.\n\nMany individuals with tic disorders have sensory and movement symptoms other than tics. A common sensory symptom is increased sensitivity to common sensations, such as glare from sunlight, tags in shirt collars, and noises from passing cars. A common movement symptom is poor handwriting and\u002For poor coordination. In one study of adolescents with tic disorder, difficulty with hand coordination predicted tic severity 7.5 years later, suggesting that sensory and\u002For motor difficulties may be a risk factor for more severe tics later in life. Despite how common they are, much is unknown about sensory and motor difficulties experienced by people with tic disorders.\n\nAdditionally, most studies of people with tics enroll younger children. As a result, little is known about sensory, motor, and psychosocial development in adolescents with tics. Knowledge of sensory and motor difficulties in adolescents with tics is important to understand because, in other adolescent populations, such difficulties are associated with worse mental and social health and worse quality of life. Deepening insight into the sensory, motor, and psychosocial development of adolescents with tic disorders is crucial to identify causes and risk factors for poor health in this population.\n\nThe goals of this study are to measure sensory and motor symptoms and function in adolescents with tics and to compare them to adolescents without tics. The research team will enroll adolescents with tics and adolescents without tics to participate in the study. Adolescent participants will complete questionnaires, electroencephalogram (EEG) tasks, and other sensory and motor tasks at baseline (with 2 study visits occurring within 30 days of each other) and 2 years later (again, with 2 study visits, occurring within 30 days of each other). A parent or other adult who knows the adolescent well will also complete questionnaires as part of the study.",[26,291],"Tic Disorder",[193,293,294,295,296,297,298,299,300,301],"tic disorder","sensorimotor","sensory","motor","sensory over-responsivity","psychosocial","development","behavioral","neurophysiology","2025-11-18",{"date":304,"type":31},"2025-11-24",{"date":306,"type":31},"2024-10-24",{"date":308,"type":20},"2030-05",{"name":118,"class":38},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":285,"sex":16,"minAge":317,"maxAge":17,"enrollmentInfo":318,"targetDuration":4,"studyType":21,"phases":320,"briefSummary":321,"conditions":322,"keywords":328,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":205},"100608585","where-wild-things-grow-nature--and-activity-based-group-interventions-for-neurodivergent-children-and-youth-100608585","NCT07203469","Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth","Where Wild Things Grow: Immediate and Long-term Impact of Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth in School, Health Care and Leisure Settings in Agder","Inclusion Criteria:\n\n* In PhD 1, participants are recruited on class-level (all) or individual (identified need).\n* In PhD 2, inclusion criteria are patients that participate in the specific interventions.\n\nExclusion Criteria:\n\n* In PhD 2, exclusion criteria include substance misuse, acute psychosis, current suicidal behavior\u002Fideation, and severe eating disorders.","5 Years",{"count":319,"type":20},240,[75],"The goal of this action research project is to develop and implement nature- and activity-based group interventions across health care, school and leisure settings in Southern Norway. The interventions are tailored to support the mental health, self-efficacy and daily life functioning of children and youth in the Agder region, with a particular focus on youngsters who struggle due to neurodivergence, such as Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) or Tourette's syndrome.\n\nThe main questions we aim to answer are:\n\n1. To what extent does nature- and activity-based outdoor education contribute to improvements in children's quality of life?\n2. To what extent does nature- and activity-based interventions in a health care setting improve children's self-efficacy, self-esteem and quality of life?\n3. Is there a difference in physiological reactions between nature-based provision of education or therapy and traditional indoor provision of education or therapy?\n\nParticipants will take part in a 12-week school-based or health care intervention.",[323,324,325,26,326,327],"Neurodevelopmental Outcomes","ADHD - Attention Deficit Disorder With Hyperactivity","Autism","Health-Related Quality-of-Life","Heart Rate Variability (HRV)",[329,330,331,332,325,333,334,335,336],"Nature-based","Action research","child and adolescent mental health","ADHD","Health-related quality of life","outdoor therapy","experiential education","heart rate variability","2025-10-01",{"date":339,"type":31},"2025-10-02",{"date":341,"type":31},"2025-09-01",{"date":343,"type":20},"2027-06-15",{"name":345,"class":346},"Sorlandet Hospital HF","OTHER_GOV",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":238,"enrollmentInfo":353,"targetDuration":4,"studyType":21,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":64},"100568328","trajectories-of-change-in-tourette-syndrome-100568328","NCT06679790","Trajectories of Change in Tourette Syndrome","Inclusion Criteria:\n\n1. Presence of chronic motor and\u002For vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months. Tics must not be due to a medical condition or the direct physiological effects of a substance.\n2. At least moderate tic severity, defined as a Yale Global Tic Severity Scale44 total score ≥14 (≥9 for those with motor or vocal tics only).\n3. Participants must be fluent in English to ensure comprehension of study measures and instructions.\n\nExclusion Criteria:\n\n1. Previous diagnosis of psychosis or cognitive disability,\n2. IQ \\\u003C 80,\n3. Substance abuse or dependence within the past year.\n4. Current suicidal intent.\n5. Changes in medication in the previous 4 weeks.",{"count":354,"type":20},30,[75],"This K23 Career Development Award is designed to provide the training needed for the PI to achieve her long-term career goal of conducting independent, programmatic intervention research in developmental populations. The training will emphasize gaining expertise in higher-intensity, multi-method, within-subject data collection and analysis. This award builds on the PI's emerging experience in tic disorders and pediatric behavioral interventions, and her ability to quickly learn and apply advanced statistical methods. The award will extend the PI's training through the following short-term training goals: 1) multi-method data collection and integration (electronic momentary assessment \\[EMA\\], wearable devices, neurocognitive tasks), 2) leading and designing pediatric clinical trials, 3) managing and analyzing large, multilevel datasets, and 4) career development and contribution to the field. The PI has developed a training plan to accomplish these goals in concert with her mentors, a team of leading experts in the fields of psychiatry and psychology, who will closely monitor training through regular meetings. The highly structured training plan also includes a set of formal coursework and workshops for each training goal to complement the hands-on experience the PI will gain from leading the research project.\n\nThe objective of this proposal is to comprehensively map symptom change across time and during a behavioral intervention for youth with Persistent Tic Disorders (PTDs). PTDs affect approximately 1% of the population, can cause significant disability, have high rates of comorbidity, and are associated with a four-fold increase in suicide risk. Research has established that tic symptoms and their change over time are highly idiographic. However, first-line, evidence-based, existing interventions are \"one-size-fits-all,\" and are only effective for 60% of patients. The current study aims to use advanced statistical methods and a novel theoretical framework to map the stability of tic patterns, along with systemic factors that relate to tic change over time. Study hypotheses, based on the literature and preliminary data, are that a) tic change patterns will be stable before intervention for all participants, b) disruption of stable patterns during the intervention phase will be associated with treatment response, and c) this disruption will depend on the specific driver of tic symptoms pre-intervention. N = 30 youth ages 12-17 with chronic tics will be recruited for the study. There will be three study phases: 1) pre-intervention (4 weeks), 2) intervention (8 weeks), and 3) post-intervention (4 weeks). Before and between each phase, participants will complete 4 traditional assessments to assess symptoms and treatment response. Throughout the 16 weeks of the study, we will collect EMA data focused on factors relevant to tics (4x per day), physiological data from wearable devices (passive, continuous), and neurocognitive task performance and tic video observation (1x per week). Results will inform efforts to develop individualized interventions for individuals with PTDs to improve treatment outcomes.",[26,84],"2025-07-31",{"date":360,"type":31},"2025-08-06",{"date":362,"type":31},"2025-03-31",{"date":364,"type":20},"2029-05-15",{"name":63,"class":38},{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":64},"100493503","strengthening-tourette-treatment-options-using-tms-to-improve-cbit-a-double-blind-randomized-controlled-study-100493503","NCT05705999","Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study","STOP-TIC","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of Tourette Syndrome\n* Moderate Tic Severity at baseline\n\nExclusion Criteria:\n\n* Presence of metallic objects or neurostimulators in the brain\n* Pregnancy\n* History of active seizures or epilepsy\n* Contraindications to receiving fMRI\n* Inability to participate in CBIT due to other underlying cognitive or medical condition","100 Years",{"count":19,"type":20},[75],"This pilot study will investigate the clinical and neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) followed by comprehensive behavioral intervention for tics (CBIT) in adult patients with Tourette's Syndrome (TS). Two groups of moderate disease severity will be randomized to receive active or sham rTMS targeted to the supplementary motor area (SMA) followed by eight CBIT sessions. The change in tic frequency and severity (primary outcome) and neurophysiological changes (secondary outcome) will be compared between the two groups. The central hypothesis is that low frequency rTMS will augment the effects of CBIT through favorable priming of the SMA network.",[26],[26,379,380],"Comprehensive Behavioral Intervention for Tics","Transcranial Magnetic Stimulation","2025-07-15",{"date":383,"type":31},"2025-07-18",{"date":385,"type":31},"2024-03-12",{"date":387,"type":20},"2026-12-30",{"name":389,"class":38},"West Virginia University",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":398,"maxAge":238,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":426},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. Have at least phrase speech, to allow for some self-report. So that results can be generalized to children and youth with NDD and various levels of ability, no IQ cut-off will be employed. Full-scale IQ (as measured by the Stanford-Binet) is measured to explore its effect on efficacy and safety\\*\n7. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n8. Ability to complete assessments in English\u002FFrench\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study","8 Years",{"count":400,"type":20},130,[50],"There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[404,325,405,406,407,408,409,332,84,26,410,411,412,413,414,415,416],"Neurodevelopmental Disorders","Autism Spectrum Disorder","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD - Combined Type","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders","2025-07-14",{"date":419,"type":31},"2025-07-16",{"date":421,"type":31},"2024-09-16",{"date":423,"type":20},"2026-09",{"name":425,"class":38},"Holland Bloorview Kids Rehabilitation Hospital",8,{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":433,"maxAge":238,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":205},"100531016","phase-2-multimodal-profiling-of-response-to-pediatric-comprehensive-behavioral-intervention-for-tics-100531016","NCT06194305","Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics","Inclusion Criteria:\n\n* Age 10-17 years at time of enrollment.\n* Current chronic motor and\u002For vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months. Tics must not be due to a medical condition or the direct physiological effects of a substance.\n* At least moderate tic severity, defined as a Yale Global Tic Severity Scale total score ≥14 (≥9 for those with motor or vocal tics only).\n* Full scale IQ greater than 70.\n* Child participant required to have English fluency to ensure comprehension of study measures and instructions.\n* To increase external validity of findings, we will include participants taking psychotropic medications that have been stable for 6 weeks and expect to remain stable for the study period. Individuals receiving non-tic related psychotherapy involving procedures that overlap with CBIT can be eligible to participate if they refrain from receiving treatment once enrolled through the post-treatment assessment. All concurrent treatments will be monitored.\n\nExclusion Criteria:\n\n* Inability to undergo MRI (e.g., metal in body, claustrophobia, orthodontia) and\u002For EEG.\n* Active suicidality Previous diagnosis of psychosis, cognitive disability, or structural brain disease that in the investigator opinion would impede participation.\n* History of seizure disorder\n* Active substance abuse or dependence.\n* Presence of another psychiatric or medical condition requiring immediate treatment and\u002For for which delay of treatment to focus on tics would be clinically inappropriate. Participants will not be excluded for comorbidities that commonly occur with TS (e.g., ADHD, OCD, anxiety) provided that this criterion is met, as only 10-15% of patients with TS have no comorbidities.\n* Concurrent psychotherapy focused on tics and\u002For involving procedures that overlap with CBIT (e.g., habit reversal therapy, exposure therapy targeting repetitive behaviors).\n* Psychotropic medication changes in the past 6 weeks and\u002For plans to change medication during the study period through post-treatment assessment.\n* ≥ 4 previous sessions of CBIT.","10 Years",{"count":153,"type":20},[50],"Tourette Syndrome and Persistent Motor\u002FVocal Tic Disorder affect 1-3% of youth and can be associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, and peer victimization. Chronic tics are the primary symptom. Comprehensive Behavioral Intervention for Tics (CBIT) is a manualized treatment focused on tic management skills. During the core CBIT procedure, competing response training, patients learn to inhibit tics by engaging in a competing motor action. The overall objective of this study is to identify bio-behavioral predictors and correlates of response and the most potent aspects of CBIT. Participants with chronic tics will complete a manualized course of 8-session CBIT. Neural, behavioral, psychosocial, and global functioning will be assessed longitudinally to examine predictors and correlates of response. CBIT sessions will be video recorded. CBIT process will be measured with a video-based behavioral coding scheme that will be refined and validated during years 1-2 using archival CBIT videos",[26,83],"2025-07-11",{"date":417,"type":31},{"date":441,"type":31},"2024-04-25",{"date":443,"type":20},"2029-02-19",{"name":63,"class":38},{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":16,"minAge":453,"maxAge":46,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":455,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":64},"100583247","cognitive-psychophysiological-treatment-for-tics-in-young-people-with-tourettes-syndrome-with-or-without-biofeedback-100583247","NCT06873841","Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback","Can the Cognitive-Psychophysiological Treatment of Tics be Optimized Through Biofeedback in Adolescents and Emerging Adults With Tourette Syndrome? - A Randomized Clinical Trial","CoBRa","Inclusion Criteria:\n\n* Have a diagnosis of TS or to experience bothersome tics;\n* Be aged 14 to 21 years inclusive at the start of therapy.\n\nExclusion Criteria:\n\n* Present a sensorimotor impairment;\n* Have a diagnosis of intellectual disability (intelligence quotient below 75);\n* Alcohol or drug abuse;\n* A neurological issue (e.g., hemifacial spasms, Huntington's disease);\n* Change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team;\n* Simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.","14 Years",{"count":73,"type":20},[75],"The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults.\n\nHypotheses:\n\n1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone.\n2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics.\n\nResearchers will compare if the biofeedback treatment will improve the severity of tics.\n\n* In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted.\n* They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section).\n* The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.",[26,53,411],[459,460,461,462,463,53,464],"CoPs","Biofeedback","cognitive-psychophysiological therapy","Tourette","Young adults","Treatment","2025-07-04",{"date":467,"type":31},"2025-07-08",{"date":469,"type":31},"2025-04-15",{"date":471,"type":20},"2029-12",{"name":473,"class":38},"Université du Québec a Montréal",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":21,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":64},"100584449","multitarget-stereotactic-electrophysiological-recording-and-stimulation-for-tourette-syndrome-100584449","NCT06889480","Multitarget Stereotactic Electrophysiological Recording and Stimulation for Tourette Syndrome","MultitArget STereotactic Electrophysiological Recording and Stimulation for Tourette Syndrome","MASTERS-TS","Inclusion Criteria:\n\n1. Age between 18 and 60 years.\n2. Diagnosis of Tourette Syndrome according to DSM-V criteria, defined as:\n\n   i. The presence of multiple motor tics and at least one vocal tic at some point (not necessarily simultaneous).\n\n   ii. Tics that have persisted for more than 1 year from their onset.\n\n   iii. Onset of tics occurring before the age of 18.\n\n   iv. The disorder is not attributable to the physiological effects of a substance or another medical condition.\n3. A Yale Global Tic Severity Scale (YGTSS) total score greater than 35 (on a scale of 0-50) for at least 1 year, with a motor tic score of ≥15, and tics being the primary cause of disability.\n4. Inadequate response to conservative treatments (standard pharmacological and behavioral therapy).\n5. Disease duration of more than 1 year.\n6. Any coexisting medical, neurological, or psychiatric disorders have been treated and remain stable for at least 6 months.\n7. A stable psychosocial environment.\n8. Neuropsychological evaluation demonstrating that the candidate can tolerate the surgical procedure, postoperative follow-up, and potential adverse events.\n9. The participant, or his\u002Fher legal representative, is able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of suicidal risk, defined as a score of ≥3 on the suicide-related items of the Hamilton Depression Rating Scale (HAMD).\n2. History of drug or alcohol dependence within the past 6 months.\n3. Abnormal brain structure as indicated by CT or MRI scans.\n4. Presence of any condition that could lead to surgical failure or interfere with postoperative management.\n5. Diagnosis of factitious disorder, malingering, or psychogenic tics.\n6. Contraindications to neurosurgical procedures (e.g., history of cerebral infarction, hydrocephalus, cerebral atrophy, or post-stroke sequelae).\n7. Contraindications for CT\u002FMRI scanning (e.g., claustrophobia).\n8. Pregnancy or lactation, or a positive pregnancy test prior to randomization.\n9. Contraindications to general anesthesia (e.g., severe arrhythmia, severe anemia, hepatic or renal dysfunction).\n10. Expected survival of less than 12 months.\n11. Participation in other interventional clinical studies that may influence outcome assessments.\n12. Any other condition that, in the investigator's judgment, renders the candidate unsuitable for participation or poses a significant risk (e.g., inability to understand study procedures or poor adherence).","60 Years",{"count":484,"type":20},5,[75],"The goal of this clinical trial is to investigate the neural mechanisms underlying Tourette syndrome (TS) and see if personalized deep brain stimulation (DBS) can help reduce tics in TS patients and improve related issues like anxiety, attention problems, and obsessive-compulsive behaviors.\n\nIn this study, researchers will use stereoelectroencephalography (SEEG) and electrocorticography (ECoG) to record brain activity in key areas involved in movement and emotion, including the nucleus accumbens (NAc), anterior limb of the internal capsule (ALIC), insular cortex, anterior cingulate cortex (ACC), central medial thalamic nucleus (CM), globus pallidus internus (GPi), and motor cortex (M1). They will test stimulation in these areas to evaluate acute therapeutic effect for each target and to identify a new effective new target.\n\nLater, participants will receive DBS treatment under three different conditions, each for 1 month to identify the optimal target:\n\n1. Stimulation at the new target,\n2. Stimulation at the CM,\n3. Sham stimulation (does not actually stimulate).\n\nFinally, DBS will be continued at the optimal target for an additional three months to confirm its therapeutic impact.\n\nBy analyzing the brain activity and comparing these conditions, the study will clarify the neural mechanisms underlying TS and learn which target works best to lower tics and improve overall quality of life for TS patients.",[26,163],[193,489,53,490,163,491],"Electrophysiology","Psychiatric Comorbidities","Biomarker","2025-05-19",{"date":494,"type":31},"2025-05-22",{"date":496,"type":31},"2024-10-01",{"date":498,"type":20},"2026-03",{"name":500,"class":38},"Beijing Tiantan Hospital",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":508,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":21,"phases":511,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":64},"100585998","multimodal-electrophysiological-study-of-cortico-subcortical-biomarkers-of-tics-in-tourette-syndrome-100585998","NCT06909656","Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome","BioTic","Inclusion Criteria:\n\n* Patient at least 16 years old.\n* Disabling and drug-resistant Tourette's syndrome.\n* Receiving deep brain stimulation treatment with implantation of the PERCEPT™ Device as part of their medical management.\n* Normal brain MRI.\n* Subject affiliated or beneficiary of a social security system.\n* Free and informed consent of the patient and, for minors, of the minor and at least one parental authority.\n\nExclusion Criteria:\n\n* Major depressive syndrome (Beck Depression Inventory (BDI-II) \\> 20).\n* MRI showing significant brain atrophy or significant hyperintensities.\n* Pregnant or nursing mothers.\n* Person unable to give personal consent.\n* Person subject to a legal protection measure (curatorship, guardianship) or placed under court protection.\n* Patient included in another research protocol with an interdiction of participation to another research or in an exclusion period","16 Years",{"count":510,"type":20},10,[75],"Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after that age. Most patients also suffer from associated psychiatric comorbidities (ADHD, OCD, mood disorders). Although the cause of TS remains unknown, the preferred hypothesis is the interaction of predisposing genetic factors and precipitating environmental factors (perinatal accidents, infectious diseases). From a pathophysiological point of view, it is widely demonstrated by structural, electrophysiological studies, functional neuroimaging, as well as by different animal models, that dysfunctions of the cortico-striato-pallido-thalamo-cortical loops (responsible for the regulation of movements, cognitive processes, and emotions) play a major role in the genesis of tics. Deep brain stimulation (DBS) treatment can be proposed as an invasive therapy in patients with severe TS resistant to usual treatments (psychotherapy, pharmacological treatments). In a well-selected population of drug-resistant patients, DBS allows an estimated overall improvement of 30 to 50% in the YGTSS score. The deep brain stimulation method currently used in TS is based on continuous (24\u002F7) and undifferentiated stimulation (fixed electrical intensity). This stimulation paradigm, devoid of adaptability to the patient's symptoms, could be at the origin of undesirable effects (related to the modulation of physiological signals), of a sub-optimal efficiency, or of an unnecessary overuse of the stimulator's capacities (battery depletion). The development of new deep brain stimulation paradigms (\"closed-loop stimulation\"), allowing the identification of pathological neuronal activity and the dynamic adaptation of stimulation parameters to these neuronal signals, requires reliable and reproducible pathological biomarker, correlated with the occurrence of tics.\n\nHowever, in TS, electrophysiological abnormalities are still not well characterized, and most of the work published on the subject were based on intraoperative recordings and needs to be confirmed on recordings at a distance from the surgery before its potential use in closed-loop stimulation paradigms. Indeed, during the first weeks after surgery, different factors tend to modify the electrophysiological signals.\n\nSeveral questions arise at the end of this healing period:\n\n* Are these pathological oscillations (distinct from the brain oscillations induced by physiological voluntary movement) still detectable weeks after the surgery?\n* What are the temporal dynamics of these oscillations around a tic?\n* What is the spatial topography of these oscillations within the GPi?\n* Is there a strong inter-individual variability?\n* How are changes in cortical activity associated with these subcortical oscillations?\n* Are the modulations of pallidal activity alone sufficient to predict the occurrence of a tic? Thus, our study aims to define precisely the cortico-subcortical activity concomitant with the occurrence of a tic, and to identify reliable and reproducible biomarker(s) associated with tics in TS.\n\nIn order to specify these biomarker(s), their temporal correlation to tic occurrence, their spatial distribution, as well as the dynamics and cortico-subcortical coherence of the identified abnormalities, we propose a prospective study on 10 patients with severe and drug-resistant TS, treated by bi-pallidal deep brain stimulation as part of routine care (no device implantation as part of the research).\n\nAn evaluation of pallidal LFP synchronized with a high-resolution video-electroencephalography recording (128 to 256 sensors) will be performed at a distance (M+\\[3-48\\]) from surgery, in order to determine the variations in pallidal and electroencephalographic activity surrounding the occurrence of tics. A control condition with voluntary (\"tic-like\") movement will be carried out in a second time, to distinguish the modifications related to the voluntary movement from those related to the occurrence of a tic. A reconstruction of the electrode positioning will be performed using the LeadDBS pipeline, and individual and group analyses will be performed to specify the mapping of pathological oscillations within the pallidum and throughout the cerebral cortex.",[26],[26,515,163],"Local field potentials","2025-04-01",{"date":518,"type":31},"2025-04-03",{"date":520,"type":31},"2025-02-17",{"date":522,"type":20},"2027-02-17",{"name":524,"class":38},"University Hospital, Bordeaux",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":532,"targetDuration":4,"studyType":21,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":64},"100576456","effect-of-rns-in-treatment-refractory-tourettes-syndrome-100576456","NCT06785532","Effect of RNS in Treatment-refractory Tourette's Syndrome","Investigating the Effect of Responsive Neurostimulation (RNS) in Patients with Treatment-refractory Tourette's Syndrome (TR-TS)","Inclusion Criteria:\n\n1. aged 18-65;\n2. able to provide written informed consent;\n3. have a diagnosis of Tourette's syndrome according to the Statistical Manual of Mental Disorders-Fourth Edition-Text Revised (DSM-IV-TR) criteria and confirmed by the Mini-International Neuropsychiatric Interview Chinese version 5.0;\n4. with a YGTSS of at least 35 for at least 12 months before surgery, while YGTSS- Total Motor≥15;\n5. must have failed conventional medical treatment at adequate therapeutic doses of three classes of medication lasting for at least three months;\n6. must not be suitable for behavioural intervention or that this intervention is inappropriate or unsuccessful;\n7. have been on stable comorbid conditions without suicidal ideation for at least six months.\n\nExclusion Criteria:\n\n1. presence of other psychotic disorders;\n2. have a treatment history that includes electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), DBS, and transcranial magnetic stimulation (TMS);\n3. presents a suicide risk (defined as a HAMD-17 score of ≥3 on suicide-related items);\n4. experience difficulty in effectively communicating with investigators;\n5. with a history of traumatic brain injury (TBI);\n6. with intracranial or cardiovascular stents;\n7. substance abuse within the past six months;\n8. unstable neurological or coagulation disorders;\n9. women who are pregnant, lactating, or of childbearing potential who refuse the use of reliable contraception during the study;\n10. have been involved in other clinical studies within three months before enrollment in this study;\n11. any conditions considered by the study group.",{"count":510,"type":20},[75],"The study is to investigate the effect of personalized responsive neurostimulation (RNS) therapy guided by stereoelectroencephalography (SEEG) in patients with treatment-resistant Tourette's Syndrome (TR-TS).",[26],[537],"TS, RNS","2025-01-19",{"date":540,"type":31},"2025-01-21",{"date":542,"type":20},"2025-02-05",{"date":544,"type":20},"2029-12-31",{"name":546,"class":38},"Xuanwu Hospital, Beijing",{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":285,"sex":16,"minAge":554,"maxAge":482,"enrollmentInfo":555,"targetDuration":4,"studyType":21,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":64},"100563204","effectiveness-of-symptom-management-application-on-parental-care-ability-of-children-with-tourette-syndrome-100563204","NCT06613126","Effectiveness of Symptom Management Application on Parental Care Ability of Children With Tourette Syndrome","Constructing and Evaluating the Effectiveness of an Intelligent Interaction System for Symptom Management on the Care Needs and Related Factors of Children With Tourette Syndrome and Their Parents","Inclusion Criteria:\n\n1. Parents of children between 6-12 years old who are diagnosed with Tourette Syndrome by pediatricians.\n2. Parents who are the primary caregivers\n3. Parents with normal cognitive functioning who can communicate in Mandarin.\n\nExclusion Criteria:\n\n1\\. Children with Tourette Syndrome who are suffering from intellectual disability or critical diseases.","20 Years",{"count":556,"type":20},180,[75],"This study developed a Tourette Syndrome (TS) symptom management application (APP) to improve the care needs, sleep quality, anxiety, quality of life, and parenting relationship of parents of children with Tourette Syndrome.",[26,291,560],"Neurodevelopmental Disorder",[562,563,564,565],"symptom management","Application","parent","children with Tourette Syndrome","2024-09-30",{"date":568,"type":31},"2024-10-03",{"date":570,"type":31},"2024-09-25",{"date":572,"type":20},"2026-07-31",{"name":574,"class":38},"National Taipei University of Nursing and Health Sciences",{"id":576,"slug":577,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":285,"sex":16,"minAge":237,"maxAge":238,"enrollmentInfo":583,"targetDuration":4,"studyType":21,"phases":584,"briefSummary":585,"conditions":586,"keywords":587,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":205},"100344444","phase-1-washed-microbiota-transplantation-for-tourettes-syndrome-100344444","NCT03764748","Washed Microbiota Transplantation for Tourette's Syndrome","Efficacy and Safety of Washed Microbiota Transplantation for Tourette's Syndrome","WMT","Inclusion Criteria:\n\n1. Patients were aged 6 to 17 years (inclusive);\n2. Met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for TS;\n3. Had a Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) of at least 20 at screening and baseline.\n4. Underwent WMT.\n\nExclusion Criteria:\n\n1. Complicated with certain brain disease, including tumor,injury,cerebrovascular disease;\n2. Complicated with other severe disease, including cancers, organ failure, heart diseases;\n3. Stereotypy associated with autism spectrum disorder;\n4. With a confirmed diagnosis of psychiatric diseases, such as bipolar disorders; schizophrenia and major depressive disorders;\n5. Clinically significant obsessive-compulsive disorder at baseline considered to be the primary cause of impairment at baseline;\n6. Medications use affecting gut microbiota such as antibiotics and probiotics three months before WMT.\n7. Other neurologic disorders other than TS that could influence the evaluation of tics.",{"count":354,"type":20},[23],"This study aimed to evaluate the efficacy of washed microbiota transplantation in the treatment of Tourette's syndrome (TS).",[26],[84,588,589,590,193],"Gut microbiota","Brain-gut axis","Washed Microbiota Transplantation","2024-08-15",{"date":593,"type":31},"2024-08-19",{"date":595,"type":31},"2024-04-17",{"date":597,"type":20},"2027-10-31",{"name":599,"class":38},"The Second Hospital of Nanjing Medical University",{"id":601,"slug":602,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":21,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":64},"100536919","internet-based-behavior-therapy-for-adults-with-tourette-syndrome-100536919","NCT06271083","Internet-based Behavior Therapy for Adults With Tourette Syndrome","A Parallel-group, Randomized Controlled Trial of Internet-based Behavior Therapy for Adults With Tourette Syndrome","TICNET","Inclusion Criteria:\n\n≥ 18 years of age.\n\nPrimary diagnosis of TS\u002FCTD, according to criteria in Diagnostic and Statistical Manual of mental disorders 5th edition.\n\nProvided digital informed consent.\n\nHave a Total Tic Severity Score (TTS) of \\>15, or \\>10 for individuals with motor or vocal tics only, in the past week, as measured by the Yale Global Tic Severity Scale (YGTSS).\n\nBeing willing and able to follow the study procedures and participate in the 10-week treatment program.\n\nBeing fluent in Swedish.\n\nHave regular access to a computer connected to the Internet, sufficient technical skills to use the treatment platform, as well as a mobile phone to receive text messages.\n\nExclusion Criteria:\n\nOngoing or planned psychological treatment for TS\u002FCTD.\n\nPrevious BT for tics of a minimum of 8 sessions with a qualified therapist within 12 months prior to assessment.\n\nAdjustment of medication for tics within the last two months prior to assessment.\n\nSevere psychiatric comorbidities such as organic brain disorders, bipolar disorder, ongoing psychosis, anorexia nervosa or substance use disorders that can interfere with the treatment for TS\u002FCTD.\n\nAcute psychiatric problems such as severe depression or suicidal risk needing immediate psychiatric care.\n\nSevere tics causing immediate risk to the participants themselves or to others and requiring urgent medical attention.",{"count":609,"type":20},110,[75],"This study protocol outlines a parallel-group, randomized controlled trial (RCT) designed to evaluate the effectiveness of Internet-delivered behavior therapy (BT) based on exposure with response prevention (ERP) for adults with Tourette syndrome (TS) or chronic tic disorder (CTD). The primary aim is to evaluate the effects of Internet-delivered ERP-based BT on tic severity compared to a control condition offering general psychological support at week 11 counting from the treatment start. The primary outcome measure is the Yale Global Tic Severity Scale - Total Tic Severity subscale (YGTSS-TTS). Secondary outcomes include measures of tics-related impairment, work and social adjustment, rates of responders, self-rated tic severity, symptoms of depression, and quality of life. Long-term maintenance of results will be assessed at week 23 and 14 months after the treatment start. Participants will be recruited nationwide. The intervention group will receive 10 weeks of ERP-based therapy delivered through an online platform, with therapist support. The control group will receive psychoeducational content and general psychological support. Adherence to treatment, adverse events, and patient safety will be closely monitored throughout the trial. The study population will be intent-to-treat and the between-group differences at the primary endpoint will be assessed using an analysis of covariance (ANCOVA) with pre-score of the measure as covariate. A health-economic evaluation will assess the cost-effectiveness of the intervention.",[26,613],"Chronic Tic Disorder","2024-02-14",{"date":616,"type":31},"2024-02-21",{"date":618,"type":31},"2024-02-02",{"date":620,"type":20},"2028-05",{"name":622,"class":38},"Karolinska Institutet"]